Acute myeloid leukemia trials in France

In France 87 Also abroad 761

87 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in France
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Lille, Pessac, Pierre-Bénite, Villejuif
Age
18 years and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Marseille, Pierre-Bénite, Toulouse, Tours
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1Taking people
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Where
Caen Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
40 worldwide
Run by
Charm Therapeutics
See details and how to joinNCT07751991 · EU 2026-526409-14-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Angers, Clermont-Ferrand, Lille, Marseille, Montpellier, Nice, Paris, Pierre-Bénite, Reims, Rennes, Toulouse, Vandœuvre Ies-Nancy, Villejuif
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 3Taking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Angers, Lille, Lyon, Nancy, Nantes, Paris, Strasbourg, Toulouse, Villejuif
Age
18 years to 75 years
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
Phase 3Taking people
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Where
Bordeaux, La Tronche, Nancy, Nice, Paris, Saint-Priest-en-Jarez, Strasbourg
Age
18 years to 71 years
People
150 worldwide
Run by
Quetzal Therapeutics
See details and how to joinNCT07504458 · EU 2025-524810-28-00
Phase 1Taking people
Study of REM-422 in Patients With AML or Higher Risk MDS
Where
Bordeaux, Paris, Toulouse, Villejuif
Age
18 years and over
People
100 worldwide
Run by
Remix Therapeutics
See details and how to joinNCT06297941
No phaseTaking people
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Where
Marseille
Age
18 years and over
People
70
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06886425
No phaseTaking people
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
Where
Strasbourg
Age
1 year and over
People
50
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT07895901
Phase 4Not yet taking people in France
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
Where
Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon Cedex 9, Bayonne, Besancon Cedex, Béziers, Bobigny Cedex, Brest, Caen, Chambéry, Clamart, Clermont-Ferrand, Corbeil Essonnes Cedex, Creteil Cedex, Dijon, Dunkirk Cedex 1, Epagny Metz-tessy, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lens, Lille, Lille Cedex, Limoges Cedex 1, Lyon, Marseille, Meaux, Metz Cedex 03, Montpellier Cedex 5, Mulhouse, Nantes, Nice, Nimes Cedex 9, Orleans Cedex 2, Paris, Perpignan Cedex, Pessac, Pierre-Bénite, Poitiers, Pontoise, Reims Cedex, Rennes, Roubaix, Rouen Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse, Tours, Vandoeuvre Les Nancy, Villejuif
Age
18 years to 64 years
People
1,290
Run by
Centre Hospitalier Universitaire De Toulouse
See details and how to join2026-525759-96-00 · EU 2026-525759-96-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Where
Amiens Cedex 1, Angers, Marseille, Nice, Paris, Pessac Cedex
Age
18 years and over
People
660 worldwide
Run by
AbbVie
See details and how to joinNCT07581002 · EU 2025-523724-47-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Angers, Caen, Creteil Cedex, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lille Cedex, Montpellier Cedex 5, Nantes, Nice, Pessac, Pierre-Bénite, Rennes Cedex 9, Rouen Cedex, Saint-Priest-en-Jarez
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Amiens Cedex 1, Angers, Bayonne, Caen Cedex 9, Le Chesnay Rocquencourt, Le Mans, Lille Cedex, Limoges Cedex 1, Marseille, Nice, Paris, Pessac, Pierre-Bénite, Rouen Cedex, Strasbourg Cedex 2
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 1Taking people
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Where
Toulouse Cedex 9, Villejuif
Age
18 years and over
People
69 worldwide
Run by
Auron Therapeutics, Inc.
See details and how to joinNCT06846606 · EU 2025-521394-13-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Béziers, Bobigny Cedex, Clermont-Ferrand, Créteil, Le Chesnay Rocquencourt, Marseille, Mulhouse, Nantes, Paris, Pessac, Pierre-Bénite, Roubaix, Rouen Cedex, Saint-Priest-en-Jarez, Vandoeuvre les Nancy, Villejuif
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Paris, Poitiers, Rennes
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Paris, Pessac, Pierre-Bénite, Villejuif
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Nantes, Paris
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Nice, Paris, Toulouse Cedex 9
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 1Taking people
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Bordeaux, Paris
Age
6 months to 17 years
People
18 worldwide
Run by
AbbVie
See details and how to joinNCT07306832
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 2Taking people
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Where
Grenoble Cedex 9, Le Mans Cedex 9, Lille, Marseille, Nice, Nîmes, Paris, Rouen
Age
18 years and over
People
191 worldwide
Run by
Ryvu Therapeutics S.A.
See details and how to join2023-505911-19-00 · EU 2023-505911-19-00
No phaseTaking people
Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
Where
Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Rennes, Rouen, Saint-Priest-en-Jarez, Sèvres, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy
People
150
Run by
Institut Claudius Regaud
See details and how to joinNCT05983991
Phase 2Taking people
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Where
Grenoble, Le Mans, Lille, Marseille, Nice, Nîmes, Paris, Rouen
Age
18 years and over
People
98 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06191263